Causes of interruption of bevacizumab therapy in age-related macular degeneration;Causas de interrupção do tratamento com bevacizumab em degeneração macular relacionada à idade

Arquivos Brasileiros de Oftalmologia

Volumn 73, Issue 2, 2010, Pages 146-149

  Nunes, Renata Portella ^a   Nóbrega, Mário Junqueira ^b   de Novelli, Fernando José ^b   Coral, Samuel Ângelo ^b   Berti, Thais Bacha ^b   Missen, Marina Maria Drumm ^c   Correa, Marina Canuto ^c  

^a Hospital Regional de São José Homero de Miranda Gomes HRSJ HMG   (Brazil)

^b Hospital de Olhos Sadalla Amin Ghanem   (Brazil)

^c University of the Region of Joinville   (Brazil)

Author keywords

Angiogenesis inhibitors therapeutic use; Bevacizumab therapeutic use; Choroidal neovascularization; Macular degeneration; Vascular endothelial growth factor A

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

AGED; ARTICLE; FEMALE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MALE; PATIENT; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; STATISTICS; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; PATIENT DROPOUTS; RETROSPECTIVE STUDIES; VITREOUS BODY;

EID: 77955348552     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492010000200009     Document Type: Article

References (18)

1. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245(1):68-73.
2. Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007; 245(7):941-8.
3. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica. 2009;223(6):401-10. Review.
4. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007;29(9):1850-61.
5. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: twoyear results of 2 randomized clinical trials - tap report 2. Arch Ophthalmol. 2001;119(2):198-207. Comment in: Arch Ophthalmol. 2005;123(9):1283-5.
6. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol. 2009; 93(6):754-8.
7. Wu L, Fernando Arevalo J, Maia M, Berrocal MH, Sanchez J, Evans T; Pan-American Collaborative Retina Study Group (PACORES). Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol. 2009; 53(2):125-30.
8. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108(6):825-31.
9. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-72.e5. Comment in: Ophthalmology. 2007;114(2):400; author reply 400-1.
10. Conrad PW, Zacks DN, Johnson MW. Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Clin Ophthalmol. 2008;2(4):727-33.
11. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from agerelated macular degeneration. Retina. 2007;27(4):432-8.
12. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):1-11. Review.
13. Bonnin P, Pournaras JC, Lazrak Z, Cohen SY, Legargasson JF, Gaudric A, et al. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age-related macular degeneration. Acta Ophthalmol. 2009 Jun 26. [Epub ahead of print]. [Internet]. 2009 [cited 2009 Jun 26]; 1-5. Avaliable from: http://www3.interscience. wiley.com/journal/122468038/abstract.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27): 2805-16. Comment in: N Engl J Med. 2005;352(16):1720-1; author reply 1720-1. ACP J Club. 2005;143(1):18. N Engl J Med. 2004;351(27): 2863-5.
15. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31.
16. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14): 1432-44.
17. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-5. Comment in: Ophthalmic Surg Lasers Imaging. 2005; 36(4):270-1.
18. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol. 2009;54(3):372-400.